FeedbackChildren and young adolescents living with HIV were eligible for enrolment in the SHINE trial. A total of 65 children and adolescents living with HIV (11%) were enrolled in the 16-week arm and 62 (10%) in the 24-week arm. The 16-week regimen was non-inferior when compared with the 24-week regimen (risk difference −4.3, 95% CI −14.9 to 6.2) (86).
Clinicians may consider treating children and adolescents living with HIV with non-severe TB for 4 months, depending on the degree of immunosuppression, ART status and presence of other opportunistic infections (90). These children and adolescents will need to be monitored closely, especially at 4 months of treatment, and treatment extended to 6 months if there is insufficient progress.